Dose Finding Study To Assess Safety, Pk And Efficacy Of Fimepinostat (Cudc‐907) With Venetoclax Or Rituximab Plus Bendamustine In Patients With Relapsed/Refractory Lymphoma by Younes, A. et al.
1Medicine/Hematology-Oncology, Weill Cornell Medical College,
New York, United States; 2Department of Medicine, Washington
University in St. Louis, St Louis, United States; 3Department of Medicine,
Memorial Sloan Kettering Cancer Center, New York, United States;
4Department of Medicine, Moffitt Cancer Center, Tampa, United States;
5Department of Pathology, Weill Cornell Medical College, New York,
United States
Introduction: Peripheral T-cell lymphomas (PTCL) are an uncommon
and heterogeneous group of non-Hodgkin lymphomas with divergent
cells of origin and mechanisms of lymphomagenesis. Cyclophospha-
mide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy,
the most commonly prescribed initial treatment for systemic PTCL,
provides suboptimal complete remission rates and response duration
in the majority of non-ALCL patients. Emerging genetic studies have
shown recurrent mutations affecting TET2, DNMT3A, IDH2 and
RHOA in PTCL subtypes, particularly in nodal peripheral T-cell lym-
phoma with T-follicular helper phenotype (PTCL-TFH) such as
angioimmunoblastic T-cell lymphoma. The association of aberrant
DNA methylation with PTCL lymphomagenesis provides rationale for
clinical application of hypomethylating agents. Azacitidine is an epige-
netic modifier of DNA methylation by inhibition of DNA methyl-
transferase at low doses. In human PTCL patients, treatment with
5-azacitidine produced sustained responses (ORR 75%, CR/Cru 50%)
in R/R AITL in a retrospective cohort study (Lemonnier et al. Blood
2018;132:2305). The feasibility of combining CHOP chemotherapy
with azacitidine has been evaluated in 2 phase 1 studies in B-cell lym-
phoma, one with injectable 5-azaticidine (Clozel et al. Cancer Discov
2013;3:1002), the other with oral azacitidine (CC-486) (Martin et al.
Blood 2017;130:192). We initiated a multi-center phase 2 study in
5/2018 to evaluate the efficacy and safety of chemo-sensitization
with oral azacitidine (CC-486) in combination with CHOP for initial
treatment of PTCL (ClinicalTrials.gov - NCT03542266).
Methods: This exploratory phase 2 study prioritizes enrollment of
nodal TCL with TFH phenotype (PTCL-TFH). Additional eligible sub-
types include PTCL/NOS and ATLL. Subjects receive standard dose
CHOP on day 1 of each cycle for a total of 6 cycles. Priming with oral
azacitidine (CC-486) at 300 mg daily is administered for 7 days prior
to CHOP cycle 1 initiation, and for 14 days (days 8-21) before CHOP
cycles 2-6. Supportive care includes mandatory G-CSF and rec-
ommended prophylaxis against PCP and VZV. The primary endpoint is
CR per 2014 IWG criteria. Secondary endpoints include ORR, safety
and survival. The study has a sample size of 20, and follows two-stage
minimax design for primary efficacy analysis. Correlative biomarker
studies are prospectively planned to assess changes in genome-wide
methylation, gene expression and immune profile in response to
DNMT inhibitor. The study is actively enrolling patients at Weill Cor-
nell Medicine, with additional 3 US sites due to open in the 2nd quar-
ter of 2019.
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Background: The 2016 WHO reclassification of lymphoid tumors dis-
tinguishes double-hit (DHL) and triple-hit (THL) lymphomas as clini-
cally important subtypes, now classified as high-grade B-cell
lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements.
Double-expressor lymphoma with MYC and BCL2 protein over-
expression without rearrangement (included within DLBCL-NOS) also
has prognostic importance. This reclassification highlights the dismal
outcomes for patients with tumors harboring MYC and/or BCL2 alter-
ations. Currently, there are no approved therapies that target MYC.
Fimepinostat (F) is an investigational small-molecule dual inhibitor of
PI3Ks and HDACs. F inhibited both PI3K and HDAC in non-clinical
studies and substantially reduced MYC protein levels. PI3K and HDAC
were also inhibited by F in patients. F demonstrated synergistic anti-
tumor effects with venetoclax (V) in DHL and DEL models in vitro and
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in vivo. In clinical studies, F as monotherapy or in combination with
rituximab (R) was well tolerated with a favorable safety profile in
patients with R/R lymphoma, and resulted in robust and durable
objective response rates (ORR) in patients with R/R MYC-altered
DLBCL.
Methods: CUDC-907-101 is a Phase 1/2, multi-center, dose-finding
study that was recently amended to study F in combination with V, or
F with R plus bendamustine (B) in pts with R/R lymphoma, including
DLBCL or HGBL with MYC and BCL2 alterations. The primary objec-
tives are to determine the MTD, safety and tolerability of each combi-
nation, and to assess preliminary efficacy, as measured by ORR and
DOR. Pts must be R/R to ≥1 prior regimen, have measurable disease
(Lugano criteria), and have archived or fresh tumor tissue. Approxi-
mately 12 pts (dose escalation; 3+3 design) and 30 pts (dose expan-
sion) will be enrolled into each combination arm. Clinical trial:
NCT01742988.
Keywords: “double-hit” lymphomas; high-grade B-cell lymphoma with
or without rearrangement of MYC and BCL2 and/or BCL6; MYC.
Disclosures: Younes, A: Consultant Advisory Role: BMS, Incyte,
Janssen, Genentech and Merck; Honoraria: Genentech, Merck, Takeda,
Incyte, BMS, AbbVie; Research Funding: Novartis, Johnson & Johnson,
Curis, Roche, BMS.
OT17
SOLAR: A PHASE 2, GLOBAL,
RANDOMIZED, ACTIVE COMPARATOR
STUDY TO INVESTIGATE THE EFFICACY
AND SAFETY OF COBOMARSEN IN
SUBJECTS WITH MYCOSIS
FUNGOIDES (MF)
A.M. James1 | J. Ruckman1 | L.A. Pestano2 |
R.D. Hopkins1 | R.C. Rodgers1 | W.S. Marshall3 |
P. Rubin3 | D. Escolar1
1Clinical & Regulatory, miRagen Therapeutics, Boulder, United States;
2Translational Science, miRagen Therapeutics, Boulder, United States;
3Management, miRagen Therapeutics, Boulder, United States
Introduction: Mycosis fungoides (MF, the most prevalent subtype of
peripheral T-cell lymphomas, is characterized by proliferation of
atypical T lymphocytes in the skin, forming patches, plaques, or nodu-
lar tumors. The goal of treatment is to minimize morbidity and limit
disease progression; however, most therapies have significant side
effects which limit their chronic use.
Cobomarsen is an inhibitor of microRNA-155, which is elevated and
plays an important role in the proliferation and survival of malignant
cancer cells in MF. In vitro, cobomarsen reduces proliferation and
increases apoptosis in lymphoma cells. A Phase I clinical trial of
cobomarsen in MF showed improvement in skin disease in 92% of
subjects, with a durable response lasting at least 4 months in 77%
of those achieving a PR (ORR4 based on mSWAT). The mean duration
of response was 276 days and no significant side effects were
attributed to cobomarsen.
Methods: MRG106-11-201 or SOLAR is a randomized, controlled,
open-label study to assess the efficacy and safety of cobomarsen in
patients with MF. The active comparator is vorinostat, an HDAC
inhibitor approved in the US for the treatment of MF. The trial is cur-
rently recruiting subjects with a target of 126 subjects (63 per arm).
Eligible subjects must have MF Stage IB-IIIB with a minimum mSWAT
score of 10, B0-1, N0-1, no visceral involvement, and no large cell
transformation. Prior treatment with an HDAC inhibitor is prohibited.
Stratification will be performed based on age and LDH level at diagno-
sis. The primary endpoint is the proportion of subjects achieving
ORR4 using composite global response criteria; secondary endpoints
include progression free survival, patient reported outcomes, time to
progression, time to next treatment, and overall survival. Subjects will
receive weekly cobomarsen 282 mg IV infusions or daily 400 mg oral
vorinostat. Assessments include changes in skin lesion severity,
disease-associated symptoms and quality of life, as well as the length
of time that the subject's disease remains stable or improved. Safety
and tolerability will include assessment of the frequency and severity
of side effects, as well as laboratory and ECG changes. Treatment will
continue until the subject becomes intolerant, develops clinically sig-
nificant side effects, progresses, or the trial is terminated.
Subjects assigned to receive vorinostat who experience confirmed
disease progression during their participation in this study may have
the option to enroll in a single arm study of cobomarsen
(MRG106-11-203 or PRISM), if they meet the entry criteria for that
study.
ClinicalTrials.gov Identifier: NCT03713320
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TABLE
Arm Cohort: Dose/Schedule
F + V 1: F 30 mg daily, 5/2 + V 400 mg QD
2: F 60 mg daily, 5/2 + V 400 mg QD
3: F 60 mg daily, 5/2 + V 800 mg QD
F + B + R 1: F 30 mg daily, 5/2 + B 90 mg/m2 Day 1,2 + R 375
mg/m2 Day 1
2: F 60 mg daily, 5/2 + B 90 mg/m2 Day 1,2 + R 375
mg/m2 Day 1
3: F 60 mg daily, 5/2 + B 120 mg/m2 Day 1,2 + R 375
mg/m2 Day 1
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